Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.12.7171

Comparison of Efficacy and Toxicity of First Line Chemotherapy with or without Epirubicin for Patients with Advanced Stage Soft Tissue Sarcoma  

Cao, Jie (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Liu, Jin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Lu, Yan-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.12, 2013 , pp. 7171-7177 More about this Journal
Abstract
Purpose: To compare the safety and efficacy of first-line chemotherapy regimen with or without doxorubicin in treating patients with advanced soft tissue sarcoma (STS). Patients and Methods: We retrospectively analyzed a cohort of 56 patients histologically confirmed with STS who were treated at Jiangsu Cancer Hospital and Research Institute from July 2011 to June 2012.The basic element of first line chemotherapy contained epirubicin in group B and lacked epirubicin in group A. Response was assessed using RECIST criteria. The Kaplan-Meier method was used to estimate progress free survival (PFS). Results: According to RECIST criteria, patients in group treated by chemotherapy without epirubicin, the objective response (OR) ratio was 6.5 % (CR0%+PR6.5%). Disease control rate (DCR=CR+PR+SD) was 25.8% with a median follow-up of 14.6 months, including 2 patients achieving a partial response (PR 6.5%) and a stable response (SD 19.4%) in 6. In group B with epirubicin based regimens, no patient had complete response, PR (28 %) was observed in 7 and SD (24 %) in 6. DCR was observed in 13 patients (52%). By Fisher's exact test, the DCR difference between the two groups was statistically significant (p=0.046). In group A, median PFS was 3.0 months (95%CI:2.1-3.8), compared with 4.0 months (95% CI:3.03-4.97) in group B (p=0.0397 by log-rank test). Epirubicin based chemotherapy and ECOG performance status 0-1 were identified as favorable factors for progression in our cohort of patients. Differences of nonhematologic and hematologic toxicities were not statistically significant between the two groups, and the addition of epirobicin was not associated with cardiac toxicity (p=0.446). Conclusion: Our study demonstrates that epirubicin-based chemotherapy is effective and well tolerated, and is superior to chemotherapy without epirubicin regarding efficacy. Therefore it is recommended that epirubicin-based chemotherapy should be considered as first line for patients with advanced STS.
Keywords
First line chemotherapy; doxorubicin; advanced stage soft tissue sarcoma; epirubicin;
Citations & Related Records
Times Cited By KSCI : 30  (Citation Analysis)
연도 인용수 순위
1 Zhan YP, Huang XE, Cao J (2012). Clinical safety and efficacy of Kanglaite (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 5319-21.   과학기술학회마을   DOI   ScienceOn
2 Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
3 Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II Study on Voriconazole in Treating Chinese Patients with Malignant Hematological Disorder and Invasive Aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.   DOI   ScienceOn
4 Shu J, Li CG, Liu YC, et al (2012).Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403.   과학기술학회마을   DOI   ScienceOn
5 Sleijfer S, Seynaeve C, Verweij J (2005). Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist, 10, 833-41.   DOI   ScienceOn
6 Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. Asian Pac J Cancer Prev, 14, 149-52.   과학기술학회마을   DOI   ScienceOn
7 Van der Graaf (2012). Phase III Randomized Study of Doxorubicin With Versus Without Ifosfamide in Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Age Range: 18 to 60 STUDY LEAD ORGANIZATION EORTC Soft Tissue and Bone Sarcoma Group Ian Robert Judson, MA, MD, FRCP, Protocol chair; 44-208-722-4302
8 Van Glabbeke M, Van Oosterom AT, Van Osterhuis JW, et al (1999). Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 17, 150-67.   DOI
9 Karavasilis V, Seddon BM, Ashley S, et al (2008). Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer, 112, 1585-91.   DOI   ScienceOn
10 Worden FP, Taylor JM, Biermann JS, et al (2005). Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF). compared with 12 $g/m^2$ of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol, 23, 105-12.   DOI   ScienceOn
11 Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22.   과학기술학회마을   DOI   ScienceOn
12 Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
13 Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
14 Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced lung adenocarcinoma cases. Asian Pac J Cancer Prev, 12, 985-7.
15 Lu YY, Huang XE, Cao J, et al (2013). Phase II study on Javanica oil emulsion injection (Yadanzi(R)) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4.   과학기술학회마을   DOI   ScienceOn
16 Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.   과학기술학회마을   DOI   ScienceOn
17 Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5.   과학기술학회마을   DOI   ScienceOn
18 Liu YC, Zhou SB, Gao F, et al (2013). Phase II study on breast conservative surgery plus chemo- and radiotherapy in treating Chinese patients with early staged breast cancer. Asian Pac J Cancer Prev, 14, 3747-50.   과학기술학회마을   DOI   ScienceOn
19 Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8.   과학기술학회마을   DOI   ScienceOn
20 Maki RG, Wathen JK, Patel SR, et al (2007). Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol, 25, 2755-63.   DOI   ScienceOn
21 NCCN Clinical Practice Guidelines in Oncology (2011). Soft Tissue Sarcoma, version 1; 10 March 2012, date last accessed
22 Maurel J, Lopez-Pousa A, de la Penas R, et al (2009). Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standrard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish Group for Research on Sarcomas. J Clin Oncol, 27, 1893-8.   DOI   ScienceOn
23 Mocellin S, Rossi CR, Brandes A, Nitti D (2006). Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev, 32, 19-27.
24 Mouridsen HT, Bastholt L, Somers R, et al (1987). Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase E1phase HI study of the EORTC soft tissue and bone sarcoma group. EurJ Cancer Clin Oncol, 23, 1477-83.   DOI
25 Penel N, Italiano A, Ray-Coquard I, et al (2012). Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol, 23, 517-23.   DOI   ScienceOn
26 Santoro A, Tursz T, Mouridsen H, et al (1995). Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 13, 1537-45.   DOI
27 Schlemmer M, Reichardt P, Verweij J, et al (2008). Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer, 44, 2433-6.   DOI   ScienceOn
28 Gu M, Li SY, Huang XE, et al (2013). A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev, 13, 5587-91.   과학기술학회마을   DOI   ScienceOn
29 Shen B, Zheng MQ, Lu JW, et al (2013). CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells. Asian Pac J Cancer Prev, 14, 5403-8.   과학기술학회마을   DOI   ScienceOn
30 Grimer R, Judson I, Peake D, Seddon B (2010). Guidelines for the management of soft tissue sarcomas. Sarcoma, 2010, 506182.
31 Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
32 Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4.   과학기술학회마을   DOI   ScienceOn
33 Karavasilis V, Seddon BM, Ashley S, et al (2008). Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma. Cancer, 112, 1585-90.   DOI   ScienceOn
34 Krikelis D, Judson I (2010). Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther, 10, 249-60.   DOI   ScienceOn
35 Kroep JR, Ouali M, Gelderblom H, et al (2011). First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST). versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study. Ann Oncol, 22, 207-14.   DOI   ScienceOn
36 Li CG, Huang XE,Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
37 Le Cesne A, Judson I, Crowther D, et al (2000). Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colonystimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 18, 2676-84.   DOI
38 Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
39 Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.   DOI   ScienceOn
40 Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-09.
41 Liu J, Huang XE, Tian GY, et al (2013). Phase II study on safety and efficacy of Yadanzi(R) (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12.   과학기술학회마을   DOI   ScienceOn
42 Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14.   과학기술학회마을   DOI   ScienceOn
43 Duffaud F, Bui BN, Penel N, et al (2008). A FNCLCC French Sarcoma Group-GETO multicenter randomized phase II study of gemcitabine (G). versus gemcitabine and docetaxel (G+D). in patients with metastatic or relapsed leiomyosarcoma (LMS). J Clin Oncol, 26, (Abstr 10511).   DOI
44 Casali PG, Blay JY (2010). Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, v198-203.   DOI   ScienceOn
45 Chen G, Shen ZL, Wang L, et al (2013). Hsa-miR-181a-5p expression and effects on cell proliferation in gastric cancer. Asian Pac J Cancer Prev, 14, 3871-5.   과학기술학회마을   DOI   ScienceOn
46 Clark MA, Fisher C, Judson I, Thomas JM (2005). Soft-tissue sarcomas in adults. N Engl J Med, 353, 701-11.   DOI   ScienceOn
47 Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev, 14, 3855-9.   과학기술학회마을   DOI   ScienceOn
48 Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of Loubo (Lobaplatin). and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7.   과학기술학회마을   DOI   ScienceOn
49 Edmonson JH, Ryan LM, Blum RH, et al (1993). Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol, 11, 1269-75.   DOI
50 Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47.   DOI   ScienceOn
51 Fayette J, Martin E, Piperno-Neumann S, et al (2007). Angiosarcomas, a herogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol, 18, 2030-6.   DOI   ScienceOn
52 Cancer Therapy Evaluation Program (2003). Common toxicity criteria. Version 3.0. Bethesda: National Cancer Institute.
53 Fei ZH, Yao CY, Yang XL, Huang XE, Ma SL (2013). Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9.   과학기술학회마을   DOI   ScienceOn
54 Fury MG, Antonescu CR, Van Zee KJ, et al (2005). A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with sugery and chemotherapy. Cancer J, 11, 241-7.   DOI   ScienceOn
55 Antman K, Crowley J, Balcerzak SP, et al (1993). An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol, 11, 1276-85.   DOI
56 Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
57 Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.   DOI   ScienceOn
58 Xu X, Wang L, Xu HQ, Huang XE, et al (2013). Clinical comparison between paclitaxel liposome (Lipusu(R)) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4.   과학기술학회마을   DOI   ScienceOn
59 Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
60 Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4.   과학기술학회마을   DOI   ScienceOn
61 Yang L, Huang XE, Xu L, et al (2013). Acidic pelvic drainage as a predictive factor for anastomotic leakage after surgery for patients with rectal cancer. Asian Pac J Cancer Prev. 14, 5441-7.   과학기술학회마을   DOI   ScienceOn
62 Yang L, Huang XE, Zhou JN (2013). Risk assessment on anastomotic leakage after rectal cancer surgery: an analysis of 753 patients. Asian Pac J Cancer Prev, 14, 4447-53.   과학기술학회마을   DOI   ScienceOn
63 Yin HT, Tian QZ, Guan L,n vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6.   과학기술학회마을   DOI   ScienceOn
64 Yin HT, Zhang DG, Wu XL, Huang XE, Chen G (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12.   과학기술학회마을   DOI   ScienceOn
65 Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.   과학기술학회마을   DOI   ScienceOn
66 Zhan YP, Huang XE, Cao J, Clinical study on safety and efficacy of Qinin (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 4773-6.   과학기술학회마을   DOI   ScienceOn
67 Wei GL, Huang XE, Huo JG, Wang XN, Tang JH (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6.   과학기술학회마을   DOI   ScienceOn